Corvus Pharmaceuticals - CRVS Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRVS shares.
View CRVS analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued twelve-month target prices for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 393.8% from the stock's current price.
View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts.

Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of the year. Since then, CRVS stock has decreased by 4.7% and is now trading at $0.81.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CRVS earnings forecast.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Sunday, October, 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.24).

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Corvus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRVS stock can currently be purchased for approximately $0.81.

Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $37.71 million. The company earns $-43,240,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.